Evolution of electromagnetic and Dirac perturbations around a black hole in Horava gravity

The evolution of electromagnetic and Dirac perturbations in the spacetime geometry of Kehagias-Sfetsos(KS) black hole in the deformed Horava-Lifshitz(HL) gravity is investigated and the associated quasinormal modes are evaluated using time domain integration and WKB methods. We find a considerable deviation in the nature of field evolution in HL theory from that in the Schwarzschild spacetime and QNMs region extends over a longer time in HL theory before the power-law tail decay begins. The dependence of the field evolution on the HL parameter $\alpha$ are studied. In the time domain picture we find that the length of QNM region increases with $\alpha$. But the late time decay of field follows the same power-law tail behavior as in the case of Schwarzschild black hole.Comment: The article was fully rewritten, references added, to appear in MPL

Thin accretion disk signatures of slowly rotating black holes in Ho\v{r}ava gravity

In the present work, we consider the possibility of observationally testing Ho\v{r}ava gravity by using the accretion disk properties around slowly rotating black holes of the Kehagias-Sfetsos solution in asymptotically flat spacetimes. The energy flux, temperature distribution, the emission spectrum as well as the energy conversion efficiency are obtained, and compared to the standard slowly rotating general relativistic Kerr solution. Comparing the mass accretion in a slowly rotating Kehagias-Sfetsos geometry in Ho\v{r}ava gravity with the one of a slowly rotating Kerr black hole, we verify that the intensity of the flux emerging from the disk surface is greater for the slowly rotating Kehagias-Sfetsos solution than for rotating black holes with the same geometrical mass and accretion rate. We also present the conversion efficiency of the accreting mass into radiation, and show that the rotating Kehagias-Sfetsos solution provides a much more efficient engine for the transformation of the accreting mass into radiation than the Kerr black holes. Thus, distinct signatures appear in the electromagnetic spectrum, leading to the possibility of directly testing Ho\v{r}ava gravity models by using astrophysical observations of the emission spectra from accretion disks.Comment: 12 pages, 15 figures. V2: 13 pages, clarifications and discussion added; version accepted for publication in Classical and Quantum Gravit

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Thermodynamics and quasinormal modes of Park black hole in Hořava gravity

We study the quasinormal modes of the massless scalar field of Park black hole in the Ho\v{r}ava gravity using the third order WKB approximation method and found that black hole is stable against these perturbation. We compare and discuss the results with that of Schwarzschild-de Sitter black hole. Thermodynamic properties of Park black hole are investigated and the thermodynamic behavior of upper mass bound is also studied.Comment: 6 pages, 8 figures, accepted for publication in EPJ

Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19

Background: We describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, one of the world’s largest international, standardized data sets concerning hospitalized patients. Methods: The data set analysed includes COVID-19 patients hospitalized between January 2020 and January 2022 in 52 countries. We investigated how symptoms on admission, co-morbidities, risk factors and treatments varied by age, sex and other characteristics. We used Cox regression models to investigate associations between demographics, symptoms, co-morbidities and other factors with risk of death, admission to an intensive care unit (ICU) and invasive mechanical ventilation (IMV). Results: Data were available for 689 572 patients with laboratory-confirmed (91.1%) or clinically diagnosed (8.9%) SARS-CoV-2 infection from 52 countries. Age [adjusted hazard ratio per 10 years 1.49 (95% CI 1.48, 1.49)] and male sex [1.23 (1.21, 1.24)] were associated with a higher risk of death. Rates of admission to an ICU and use of IMV increased with age up to age 60 years then dropped. Symptoms, co-morbidities and treatments varied by age and had varied associations with clinical outcomes. The case-fatality ratio varied by country partly due to differences in the clinical characteristics of recruited patients and was on average 21.5%. Conclusions: Age was the strongest determinant of risk of death, with a ~30-fold difference between the oldest and youngest groups; each of the co-morbidities included was associated with up to an almost 2-fold increase in risk. Smoking and obesity were also associated with a higher risk of death. The size of our international database and the standardized data collection method make this study a comprehensive international description of COVID-19 clinical features. Our findings may inform strategies that involve prioritization of patients hospitalized with COVID-19 who have a higher risk of death